NDLI: Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.

Please wait, while we are loading the content...

A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.

Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Oncolytic viruses: From bench to bedside with a focus on safety.

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.

Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus.

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue

Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood.

Influence of sources of information about influenza vaccine on parental attitudes and adolescent vaccine receipt.

Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains

New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters

A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix™ in healthy adults.

Safety assessment of adjuvanted vaccines: Methodological considerations.

Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.

Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.

Preclinical development of HIvax: Human survivin highly immunogenic vaccines.

Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic.

Overcoming nutrient limitations for cell-based production of influenza vaccine.

Early estimates of 2014/15 seasonal influenza vaccine effectiveness in preventing influenza-like illness in general practice using the screening method in France

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents--A single blind randomized trial.

Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.

3rd ESCMID conference on vaccines in Lisbon, Portugal: Vaccines for mutual protection.

Validation of infant immunization billing codes in administrative data.

A correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants.

Measles vaccination and prevention in big cities in China.

Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.

Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.

Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Intussusception following rotavirus vaccination in the Valencia Region, Spain.

Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.

Inadequate activation of the HBsAg-specific Th cells by APCs leads to hyporesponsiveness to HBsAg vaccine in B10.S mice

Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.

Investigation into alternative testing methodologies for characterization of influenza virus vaccine.

Letter from the Editor.

Human Vaccines and Immunotherapeutics: News.

My passion is to drive innovation in vaccine development.

The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.

Erratum.

Corrigendum.

Year: 2015 Volume: 11 Issue: 6

Year: 2015 Volume: 11 Issue: 5

Year: 2015 Volume: 11 Issue: 4

Year: 2015 Volume: 11 Issue: 3

Year: 2015 Volume: 11 Issue: 2

Year: 2015 Volume: 11 Issue: 1

Year: 2014 Volume: 10

Year: 2013 Volume: 9

Year: 2012 Volume: 8

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Van Der Meeren, Olivier Crasta, Priya Cheuvart, Brigitte De Ridder, Marc
Description	Country affiliation: Belgium Author Affiliation: Van Der Meeren O ( a GSK Vaccines )
Abstract	The immune system becomes less effective with age, and older age is associated with an increased susceptibility to diseases and reduced responses to vaccination. Furthermore, some adult populations, such as those with diabetes mellitus, are at increased risk of acute hepatitis B virus (HBV) infection. Decreasing responses to vaccination with advanced age have been described, but it is not known at what age immunogenicity starts to reduce, or until what age immunogenicity remains acceptable (for example ≥ 80% seroprotection post-vaccination). We characterized the relationship between age and seroprotection rate induced by recombinant HBV vaccination by conducting a pooled analysis of clinical trial data. Healthy adults aged ≥ 20 y who had been vaccinated with 20 µg HBV vaccine (Engerix™ B, GSK Vaccines, Belgium) in a 0, 1, 6 months schedule in 11 studies since 1996 were included. The observed seroprotection rate, defined as an anti-HBV surface antigen antibody concentration ≥ 10 mIU/ml was 94.5% in the whole population (N = 2,620, Total vaccinated cohort), ranging from 98.6% in adults vaccinated at age 20-24 years, to 64.8% in those vaccinated at age ≥ 65 y A model on seroprotection rates showed a statistically significant decrease with age, and predicted that the anti-HBs seroprotection rate remains ≥ 90% up to 49 y of age and ≥ 80% up to 60 y of age. Individuals at risk of HBV infection should be vaccinated as early in life as possible to improve the likelihood of achieving seroprotection. Additional studies are needed to identify whether unvaccinated individuals older than 60 y would benefit from regimens that include additional or higher vaccine doses.
File Format	HTM / HTML
ISSN	21645515
e-ISSN	2164554X
DOI	10.1080/21645515.2015.1039758
Journal	Human Vaccines & Immunotherapeutics
Issue Number	7
Volume Number	11
Language	English
Publisher	Taylor & Francis
Publisher Date	2015-01-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Discipline Therapeutics Hepatitis B Vaccines Therapeutic Use Aging Immunology Hepatitis B Prevention & Control Hepatitis B Antibodies Hepatitis B Surface Antigens Immunization Schedule Vaccines, Synthetic Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis

Optimal vaccination program for healthy adults in China.

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules.

Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.

Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B.

The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy.

Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.

Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals.

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.

Similar Documents

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis

Optimal vaccination program for healthy adults in China.

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules.

Comparison of the effect of two different doses of recombinant hepatitis B vaccine on immunogenicity in healthy adults.

Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B.

The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy.

Persistence of immunity in healthy adults aged ≥ 50 years primed with a hepatitis B vaccine 3 years previously.

Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals.

Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis.